Hubei Cancer Hospital

Response-Adapted Postoperative Therapy Following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: a phase II trial

Neoadjuvant chemo-immunotherapy (NACI) demonstrates promising efficacy in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), yet its effect on postoperative radiotherapy/chemoradiotherapy (PORT/POCRT) remains undefined. This open-label phase 2 study (NCT05476965)...

Transformer‐Based Multitask Framework Integrating Habitat and Deep Learning for Predicting Early Disease Control and Survival in Immunotherapy‐Treated Hepatocellular Carcinoma

ABSTRACT Hepatocellular carcinoma (HCC) patients show heterogeneous responses to immune checkpoint inhibitors (ICIs). This study developed ECOS‐Net, a transformer‐based multitask network integrating CT‐derived habitat and 2.5‐dimensional (2.5D) deep learning features for simultan...

Core-shell Au@HOF nanoradiosensitizers activate potent immunogenic cell death for enhanced radio–radiodynamic–immunotherapy

Radiotherapy (RT) efficacy is constrained by inefficient radiation utilization and inadequate systemic immunity. Although nanoparticle-based radiosensitizers aim to enhance therapeutic outcomes, most existing systems lack effective integration of radiation enhancement, dynamic th...

Radiotherapy and immunotherapy for oligometastatic hepatoid adenocarcinoma arising from endometriosis: a case report

Abstract Objectives Hepatoid adenocarcinoma (HAC) arising from endometriosis is an extremely rare malignancy with a poor prognosis and no standard treatment. Radical surgical resection followed by chemotherapy is the commonly used treatment for HAC. The role of radiotherapy and i...

Recent advances in anticoagulant-related nephropathy: risk factors, peribiopsy and therapeutic anticoagulation

Abstract The concept of anticoagulant-related nephropathy (ARN), first proposed in 2009, manifests as acute kidney injury or the rapid deterioration of chronic kidney disease secondary to anticoagulant therapy. Large numbers of tubular RBCs and/or tubular RBC casts and ATN, witho...

The association between a novel visceral lipoprotein risk index and new-onset diabetes in middle-aged and older Chinese adults

Abstract Background The global health burden of diabetes continues to grow. While the Chinese Visceral Adiposity Index (CVAI) and low-density lipoprotein cholesterol (LDL-C) are well-established risk factors for diabetes, the potential compounding effect of these factors is not w...

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites...

Signal Detection and Temporal Analysis of Aromatase Inhibitor‐Associated Hepatotoxicity: A Pharmacovigilance Study Integrating Bayesian Belief‐Propagation Network and Frequentist Metrics

ABSTRACT Background This study assessed the real‐world hepatotoxicity of third‐generation aromatase inhibitors (AIs) for breast cancer using pharmacovigilance approaches. Methods FAERS data (Q1 2004–Q1 2025) were analysed using a data‐driven disproportionality analysis framework...